Anonymous
Guest
Anonymous
Guest
From Bloomberg. The analyst guessing game. Of course sales goals will naturally be aiming somewhere in the 5 billion dollar market Good luck.
Jeffrey Holford, an analyst with Jefferies International Ltd., wrote in a note today that he has reduced his peak sales estimate for the drug to $1 billion from $2 billion, citing the warning on the label and the introduction of generic Plavix in the U.S. during the second quarter of next year.
Tim Anderson, an analyst with Sanford C. Bernstein & Co. in New York, said he has a “more modest” sales estimate of $750 million in 2015 due to the introduction of generic Plavix.
“We think the biggest impediment to Brilinta’s uptake will be the availability of generic Plavix, which will be available at a fraction of the price of Brilinta,” Anderson wrote in a note to investors last night.
Jeffrey Holford, an analyst with Jefferies International Ltd., wrote in a note today that he has reduced his peak sales estimate for the drug to $1 billion from $2 billion, citing the warning on the label and the introduction of generic Plavix in the U.S. during the second quarter of next year.
Tim Anderson, an analyst with Sanford C. Bernstein & Co. in New York, said he has a “more modest” sales estimate of $750 million in 2015 due to the introduction of generic Plavix.
“We think the biggest impediment to Brilinta’s uptake will be the availability of generic Plavix, which will be available at a fraction of the price of Brilinta,” Anderson wrote in a note to investors last night.